Naperville, IL -- (SBWire) -- 03/05/2015 --Reportstack, provider of premium market research reports announces the addition of EpiCast Report: Insomnia - Epidemiology Forecast to 2023 market report to its offering

EpiCast Report: Insomnia - Epidemiology Forecast to 2023

Summary

The publisher epidemiologists forecast that the total prevalent cases of acute insomnia in the 7MM will increase from 121,799,911 total prevalent cases in 2013, to 130,482,156 total prevalent cases in 2023 at an Annual Growth Rate (AGR) of 0.71%. The publisher epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to 67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The 7MM had an estimated 23,690,040 total prevalent cases of chronic primary insomnia in 2013 and the number of total prevalent cases is expected to increase to 25,378,728 by 2023, at an AGR of 0.71%. The publisher epidemiologists forecast that the total prevalent cases of chronic secondary insomnia in the 7MM will increase from 53,697,425 total prevalent cases in 2013, to 57,525,122 total prevalent cases in 2023 at an AGR of 0.71%.

Insomnia is a highly prevalent condition; approximately one third of the general population presents with some degree of insomnia.

The publisher epidemiologists used comprehensive country-specific data from population-based studies published in peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia in the 7MM, based on the DSM-IV criteria. For all the 7MM, the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia were segmented by age and sex, which facilitates an understanding of the distribution of the disease within the population and informs strategies to improve the management of the disease. Furthermore, the forecast methodology is consistent across each of the 7MM, thereby allowing for a meaningful comparison of the forecast total prevalent cases among each market.

Scope

- The Insomnia EpiCast Report providess an overview of the risk factors, comorbidities, and the global and historical trends for insomnia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia, segmented by sex and age (in 15-year age groups beginning at 15 years and ending at =75 years) in these markets.

- The insomnia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global insomnia market.

- Quantify patient populations in the global insomnia market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for insomnia therapeutics in each of the markets covered.

Complete report is available
http://www.reportstack.com/product/193588/epicast-report-insomnia-epidemiology-forecast-to-2023.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604